| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Susan M. Ramin | Q110252023 |
| P2093 | author name string | Yang Xia | |
| Rodney E Kellems | |||
| P2860 | cites work | Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. | Q24537348 |
| Early growth response proteins (EGR) and nuclear factors of activated T cells (NFAT) form heterodimers and regulate proinflammatory cytokine gene expression | Q24550502 | ||
| Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration | Q28610258 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo | Q31404999 | ||
| Oxidative stress in the pathogenesis of preeclampsia | Q33796834 | ||
| The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis | Q33838726 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Preeclampsia: what we know and what we do not know | Q33858363 | ||
| Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. | Q33930029 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| Pre-eclampsia | Q34079933 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Recent Insights into the pathogenesis of pre-eclampsia | Q34682287 | ||
| Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. | Q34702420 | ||
| Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells | Q35554163 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Genetic progress towards the molecular basis of autoimmunity. | Q36368037 | ||
| The renin-angiotensin-aldosterone system in preeclampsia. A review | Q36453940 | ||
| The immune system and happiness. | Q36617511 | ||
| Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin | Q37369504 | ||
| The renin-angiotensin system in pregnancy and parturition | Q39587865 | ||
| Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia | Q40530224 | ||
| Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: morphological and biochemical evidence | Q41098649 | ||
| Placental cytokines and the pathogenesis of preeclampsia | Q41452017 | ||
| Lymphocyte intracellular free calcium concentration is increased in preeclampsia | Q42472176 | ||
| Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction | Q43744794 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
| Increased intracellular free calcium and sensitivity to angiotensin II in platelets of preeclamptic women | Q46136176 | ||
| Preeclamptic Sera Stimulate Increased Platelet-Derived Growth Factor mRNA and Protein Expression by Cultured Human Endothelial Cells | Q46190634 | ||
| Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia | Q46305789 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion | Q46877931 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Agonistic AT1 receptor autoantibodies and monocyte stimulation in hypertensive patients*1 | Q47447775 | ||
| Endothelial dysfunction in preeclampsia | Q47879591 | ||
| Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. | Q51139503 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia | Q56619500 | ||
| Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia | Q58778301 | ||
| Erythrocyte cation metabolism in preeclampsia | Q69354420 | ||
| Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen | Q71695937 | ||
| Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression | Q73076634 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Pathophysiology of pregnancy-induced hypertension | Q74039094 | ||
| Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences | Q79260245 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia | Q82705098 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| autoantibody | Q785022 | ||
| pathophysiology | Q1135939 | ||
| P304 | page(s) | 269-275 | |
| P577 | publication date | 2007-06-18 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia | |
| P478 | volume | 50 |
| Q37132801 | AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia |
| Q35994304 | Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats |
| Q37800883 | Aetiology and physiopathology of preeclampsia and related forms |
| Q36355165 | Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia |
| Q45965532 | Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade. |
| Q47799852 | Angiogenic imbalance and diminished matrix metalloproteinase-2 and -9 underlie regional decreases in uteroplacental vascularization and feto-placental growth in hypertensive pregnancy |
| Q35576417 | Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction |
| Q36683260 | Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q35701236 | Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice |
| Q47646984 | Angiotensin vaccination: what is the prospect of success? |
| Q37436219 | Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats |
| Q35681804 | Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling |
| Q28083815 | Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia |
| Q38220404 | Constitutive activity in the angiotensin II type 1 receptor: discovery and applications |
| Q47653060 | Decreased maternal plasma apelin concentrations in preeclampsia |
| Q26852668 | Elucidating immune mechanisms causing hypertension during pregnancy |
| Q37229246 | Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia |
| Q37353537 | Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy |
| Q37331931 | Exercise, vascular wall and cardiovascular diseases: an update (Part 1). |
| Q83799951 | Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension |
| Q37447371 | Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. |
| Q34355945 | Increased xanthine oxidase in the skin of preeclamptic women |
| Q39198610 | Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase |
| Q89454188 | Lipoxin A4 suppresses angiotensin II type 1 receptor autoantibody in preeclampsia via modulating caspase-1 |
| Q46342648 | Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia |
| Q37136212 | Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia |
| Q58589187 | Molecular Determinants of Microvascular Dysfunction in Hypertensive Pregnancy and Preeclampsia |
| Q38017497 | Pathogenesis of pre-eclampsia: marinobufagenin and angiogenic imbalance as biomarkers of the syndrome |
| Q54119733 | Placental Growth Factor Reverses Decreased Vascular and Uteroplacental MMP-2 and -9 and increased MMP-1 and -7 and Collagen I and IV in Hypertensive Pregnancy. |
| Q90259719 | Placental Origins of Preeclampsia: Potential Therapeutic Targets |
| Q24320230 | Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease |
| Q37079628 | Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia |
| Q42356968 | Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy |
| Q27009109 | Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract |
| Q34785813 | Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia |
| Q36767058 | Serum agonistic autoantibodies against type-1 angiotensin II receptor titer in patients with epithelial ovarian cancer: a potential role in tumor cell migration and angiogenesis |
| Q37088970 | The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia |
| Q36597244 | Utero-placental expression of angiotensin-(1-7) and ACE2 in the pregnant guinea-pig |
| Q36699839 | Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia |
Search more.